Get the latest news, insights, and market updates on GELS (Gelteq Limited). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Gelteq and Healthy Extracts to Expand Gel-Based Nutrition Technologies with New Strategic Manufacturing & Commercial Partnership
MELBOURNE, Australia and LAS VEGAS, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq”) and Healthy Extracts™ Inc. (“Healthy Extracts”) today announced the signing of a Memorandum of Understanding (“MoU”) formalising a strategic partnership designed to accelerate the commercial rollout of next-generation gel-based nutraceutical products. The collaboration builds on Healthy Extracts’ prior purchases of Gelteq-formulated products and marks the first phase of a long-term plan to bring Gelte Feb 11, 2026 - $GELS
Gelteq announces preclinical results on medicinal cannabinoid absorption
Gelteq (GELS) announced positive results from a recently completed preclinical study which evaluated medicinal cannabinoids delivery through the Company’s proprietary oral gel platform. The findings demonstrate that Gelteq’s platform significantly enhances the absorption and bioavailability of cannabidiol compared to an existing FDA approved oil-based product. Despite having a much lower concentration of CBD, Gelteq’s formulation achieved greater than 22% increase in bioavailability along with a Jan 14, 2026 - $GELS
Gelteq Announces Positive Preclinical Results Showing Increased Medicinal Cannabinoid Absorption Using Its Oral Gel Delivery Platform
MELBOURNE, Australia, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”), a clinical and science-based developer of advanced gel-based oral delivery systems, today announced positive results from a recently completed preclinical study which evaluated medicinal cannabinoids delivery through the Company’s proprietary oral gel platform. The findings demonstrate that Gelteq’s platform significantly enhances the absorption and bioavailability of cannabidiol (“CBD”) compared Jan 13, 2026 - $GELS
Gelteq Furthers Asia Presence Through Partnership with Hong Kong Flag Football Program
Collaboration Combines Growing International Interest in Gelteq’s Sports Science Technology with Rising Interest in Flag Football Ahead of 2028 Summer Olympic Games Debut in Los AngelesMELBOURNE, Australia, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”), a clinical and science-based company specialising in gel-based oral delivery solutions, today announced a new partnership with the Hong Kong Flag Football Program. The partnership will integrate Gelteq’s advanced hy Dec 16, 2025 - $GELS
Gelteq Signs Three Year Sales Agreement with Shenzhen Mana Health Management Co. Strengthening Gelteq’s Nutritional Product Expansion into China
Agreement includes minimum annual order commitments totalling approximately USD $1.3 millionMELBOURNE, Australia, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”), a clinical and science based innovator in gel based oral delivery technologies, today announced that it has entered into a three year sales agreement with Shenzhen Mana Health Management Co. Ltd. (“Mana”) under which Mana will distribute consumer nutritional products within China using Gelteq’s proprietary Dec 9, 2025 - $GELS
Gelteq Preclinical Study Demonstrates Enhanced Oral Delivery of Oil-Soluble and Poorly Soluble Drugs Using Its Gel-Based Platform
MELBOURNE, Australia, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”), a clinical and science-based developer of advanced gel-based oral delivery systems, today announced preclinical findings demonstrating the effectiveness, flexibility, and safety profile of its proprietary gel platform. The results address a major challenge in pharmaceutical development and demonstrate that Gelteq’s technology can enhance the oral delivery of oil-soluble and poorly soluble drugs. A Dec 5, 2025 - $GELS
Gelteq to Present at Investor Summit Virtual on December 9, 2025
MELBOURNE, Australia, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (Nasdaq: GELS) (“Gelteq”) today announced that Nathan Givoni, its Chief Executive Officer, will present at the Q4 Investor Summit Virtual on December 9, 2025, where he will share updates on Gelteq’s growth strategy, market positioning, and upcoming catalysts. The Investor Summit is an exclusive virtual event connecting investors with disruptive small and microcap companies. This quarter’s event highlights MicroCap companies w Dec 2, 2025 - $GELS
Gelteq Announces Positive Preclinical Results Demonstrating Enhanced Bioavailability Using Its Proprietary Gel-Based Drug Delivery Platform
Findings Anticipated to Unlock Broad New Commercial Opportunities Across Water-Soluble Drug ClassesMELBOURNE, Australia, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”), a clinical and science-based company specialising in gel-based oral delivery solutions, today announced positive preclinical results showing its proprietary gel formulation achieved substantially higher bioavailability than a leading on-market reference antihistamine product. In a comparative pharmac Nov 24, 2025 - $GELS
Gelteq Announces Commencement of Preclinical Trial Targeting Oil Soluble Drug Market with Novel Delivery Platform
Collaboration with Monash University to Address a Large Pharmaceutical OpportunityMELBOURNE, Australia, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”), a clinical and science-based company specialising in gel-based oral delivery solutions, today announced it has started a preclinical animal trial evaluating its proprietary formulation technology for oily and poorly soluble drugs. Gelteq will conduct the study with Monash University Institute of Pharmaceutical Scienc Oct 23, 2025 - $GELS
Gelteq Announces New Product Development Agreement with Melbourne Health for Novel Bowel Polyp Growth Reduction Compound
MELBOURNE, Australia, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”), a clinical and science-based company specialising in gel-based oral delivery solutions, today announced it has entered into a Product Development and Profit Share Agreement (the “Agreement”), with Melbourne Health (“Melbourne Health”), operator of The Royal Melbourne Hospital and one of Australia’s top public health services with extensive research capabilities. Under the Agreement, Gelteq and Mel Oct 9, 2025 - $GELS
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple